2 búsqueda de la palabra clave 'effectiveness'

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma / Kenny Mauricio Gálvez Cárdenas    

Público ISBD Título : Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Fecha de publicación : 2021 Títulos uniformes : Future Oncology Idioma : Inglés (eng) Palabras clave : effectiveness  ixazomib  multiple myeloma  proteasome inhibitor  relapsed/refractory  routine clinical practice Resumen : Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Mención de responsabilidad : Roman Hájek, Jiri Minarík, Jan Straub, Ludek Pour, Alexandra Jungova, Jesus G Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L Costello, Faith E Davies, Vania TM Hungria, Hans C Lee, Xavier Leleu, Noemi Puig, Robert M Rifkin, Evangelos Terpos, Saad Z Usmani, Katja C Weisel, Jeffrey A Zonder, Magda Barinová, Matyáš Kuhn, Jirí Šilar, Lenka Cápková, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren & Vladimír Maisnar Referencia : Future Oncol. 2021 Mar 26. DOI (Digital Object Identifier) : 10.2217/fon-2020-1225 PMID : 33769076 Derechos de uso : CC BY-NC-ND En línea : https://www.futuremedicine.com/doi/10.2217/fon-2020-1225 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5786 Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma [documento electrónico] / Kenny Mauricio Gálvez Cárdenas,  . - 2021. Obra : Future Oncology Idioma : Inglés (eng) Palabras clave : effectiveness  ixazomib  multiple myeloma  proteasome inhibitor  relapsed/refractory  routine clinical practice Resumen : Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Mención de responsabilidad : Roman Hájek, Jiri Minarík, Jan Straub, Ludek Pour, Alexandra Jungova, Jesus G Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L Costello, Faith E Davies, Vania TM Hungria, Hans C Lee, Xavier Leleu, Noemi Puig, Robert M Rifkin, Evangelos Terpos, Saad Z Usmani, Katja C Weisel, Jeffrey A Zonder, Magda Barinová, Matyáš Kuhn, Jirí Šilar, Lenka Cápková, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren & Vladimír Maisnar Referencia : Future Oncol. 2021 Mar 26. DOI (Digital Object Identifier) : 10.2217/fon-2020-1225 PMID : 33769076 Derechos de uso : CC BY-NC-ND En línea : https://www.futuremedicine.com/doi/10.2217/fon-2020-1225 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5786

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001715	AC-2021-036	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2021-036 Adobe Acrobat PDF

Effectiveness of an secondary prevention program in chronic kidney disease / Carlos Enrique Yepes Delgado    

Público ISBD Título : Effectiveness of an secondary prevention program in chronic kidney disease Tipo de documento : documento electrónico Autores : Carlos Enrique Yepes Delgado, Fecha de publicación : 2013 Títulos uniformes : Open Journal of Nephrology Idioma : Inglés (eng) Palabras clave : Chronic kidney disease  renal protection program  effectiveness  clinical markers  progression of renal damage  renal replacement program Resumen : Background: There are many programs which focus on late-stage chronic kidney disease (CKD), and it is considered that further evidence needs to be generated regarding the effectiveness of the programs used before renal replacement therapy. Study Design: A cohort study. Settings & Participants: Patients over 15 years of age who had been diagnosed with CKD according to the KDOQI (Kidney Disease Outcomes Quality Initiative) guidelines and who had undergone conventional treatment (CT) or a renal protection program (RPP). These were patients of two Colombian health insurance companies. Predictors: Age, sex, marital status, comorbidities, CKD stage, and clinical indicators. Outcomes: First CKD progression, and need for renal replacement therapy (RRT). Measures: Clinical marker. Results: The RPP is structurally and functionally different from the CT. It offers the interdisciplinary management of patients, a greater number of medical appointments, and patients start to receive treatment at younger ages and at earlier stages of their condition. The clinical markers of the patients following the RPP are within adequate ranges, and their renal function is less impaired, despite the differences in basal conditions. Upon finishing the study, we found that patients who received CT had a higher risk of receiving nephrotoxic drugs and not receiving nephroprotective drugs. The explanatory variables for the first progression were age, stage, history of dyslipidemia, and hemoglobin, potassium, and albumin levels. These variables, together with glycemia levels were also valid for RRT, except for history of dyslipidemia, as it was not significant. Upon adjusting for the explanatory variables, it was found that belonging to the RPP and attending more appointments had a protective effect in the process of controlling renal damage. Limitations: A possible selection bias. Conclusions: Belonging to a structured renal protection program is an effective way to keeping the clinical markers associated with renal impairment within normal ranges. Mención de responsabilidad : Carlos Enrique Yepes Delgado, Yanett Marcela Montoya Jaramillo, Beatriz Elena Orrego Orozco, Paulina Bernal Ramírez, Luz Denise González, José Miguel Abad Echeverri, María Patricia Arbeláez Montoya Referencia : OJNeph. 2013;3(3):139-47. DOI (Digital Object Identifier) : 10.4236/ojneph.2013.33026 Derechos de uso : CC BY En línea : http://www.scirp.org/journal/paperinformation.aspx?paperid=36760 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3695 Effectiveness of an secondary prevention program in chronic kidney disease [documento electrónico] / Carlos Enrique Yepes Delgado,  . - 2013. Obra : Open Journal of Nephrology Idioma : Inglés (eng) Palabras clave : Chronic kidney disease  renal protection program  effectiveness  clinical markers  progression of renal damage  renal replacement program Resumen : Background: There are many programs which focus on late-stage chronic kidney disease (CKD), and it is considered that further evidence needs to be generated regarding the effectiveness of the programs used before renal replacement therapy. Study Design: A cohort study. Settings & Participants: Patients over 15 years of age who had been diagnosed with CKD according to the KDOQI (Kidney Disease Outcomes Quality Initiative) guidelines and who had undergone conventional treatment (CT) or a renal protection program (RPP). These were patients of two Colombian health insurance companies. Predictors: Age, sex, marital status, comorbidities, CKD stage, and clinical indicators. Outcomes: First CKD progression, and need for renal replacement therapy (RRT). Measures: Clinical marker. Results: The RPP is structurally and functionally different from the CT. It offers the interdisciplinary management of patients, a greater number of medical appointments, and patients start to receive treatment at younger ages and at earlier stages of their condition. The clinical markers of the patients following the RPP are within adequate ranges, and their renal function is less impaired, despite the differences in basal conditions. Upon finishing the study, we found that patients who received CT had a higher risk of receiving nephrotoxic drugs and not receiving nephroprotective drugs. The explanatory variables for the first progression were age, stage, history of dyslipidemia, and hemoglobin, potassium, and albumin levels. These variables, together with glycemia levels were also valid for RRT, except for history of dyslipidemia, as it was not significant. Upon adjusting for the explanatory variables, it was found that belonging to the RPP and attending more appointments had a protective effect in the process of controlling renal damage. Limitations: A possible selection bias. Conclusions: Belonging to a structured renal protection program is an effective way to keeping the clinical markers associated with renal impairment within normal ranges. Mención de responsabilidad : Carlos Enrique Yepes Delgado, Yanett Marcela Montoya Jaramillo, Beatriz Elena Orrego Orozco, Paulina Bernal Ramírez, Luz Denise González, José Miguel Abad Echeverri, María Patricia Arbeláez Montoya Referencia : OJNeph. 2013;3(3):139-47. DOI (Digital Object Identifier) : 10.4236/ojneph.2013.33026 Derechos de uso : CC BY En línea : http://www.scirp.org/journal/paperinformation.aspx?paperid=36760 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3695

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000268	AC-2013-036	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2013-036.pdf Adobe Acrobat PDF